Business
Incyte to Buy Vega Therapeutics For Up to $2 Billion
Incyte INCY -1.70%decrease; red down pointing triangle has agreed to buy Vega Therapeutics for up to $2 billion in a deal that expands the biopharmaceutical company’s hematology portfolio into bleeding disorders.
Incyte on Monday said it will pay an initial $1.25 billion in cash to acquire Vega from privately held Star Therapeutics, which will be eligible to receive up to $750 million in additional payments based on sales milestones.
Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
You must be logged in to post a comment Login